CD47 and neoplasm: CD47-targeting therapies have extensive preclinical validation, and targeting CD47 with monoclonal antibodies (MAbs) in xenograft models of ovarian, colon, breast, bladder, lung, pancreatic carcinoma, glioma, and leiomyosarcoma enhances macrophage activity and tumor elimination [29,45,46].